Table 1.
Preclinical efficacy of rVSV vectors
| Immunogen1/Route2 | Challenge1/Route2 | Species | Reference |
|---|---|---|---|
| HIVenv, SIVgag/IN, IM | SHIV/IV, Vaginal | Rhesus macaques | [19, 20, 78, 89] |
| Flu HA/IN | Flu/IN | Mice | [84, 85] |
| RSV F or G/IN | RSV/IN | Mice | [49, 50] |
| SARS S/IN | SARS/IN | Mice | [51] |
| MV HN/IN | MV/IN | Cotton rats | [94] |
| CRPV L1/IN, IM | CRPV/ID | Rabbits | [82] |
| EBOVgp/IM | EBOV/IM | Cynomolgus macaques | [44] |
| MARVgp/IM | MARV/IM | Cynomolgus macaques | [44] |
| LVgp/IM | LV/IM | Cynomolgus macaques | [33] |
| HSV-2gD/IN, IM | HSV-2/Vaginal | Mice, guinea pigs | [69] |
1Flu HA Influenza A hemagglutinin, RSV respiratory syncytial virus, SARS S severe acute respiratory syndrome coronavirus spike protein, MV HN measles virus HA/neuraminidase, CRPV L1 cottontail rabbit papilloma virus L1 protein, EBOVgp Ebola virus glycoprotein, MARV gp Marburg virus glycoprotein, LVgp Lassa fever virus glycoprotein, HSV-2gD herpes simplex type 2 gD glycoprotein
2IN intranasal, IM intramuscular, ID intradermal, and IV intravenous